Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule
Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...
FiercePharma5d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
HealthDay on MSN6d
Guidance Developed for Diagnosis, Management of Eosinophilic Esophagitis
HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...
pharmaphorum2d
ICER says Amgen's tezepelumab 'likely to be too expensive'
That's less than the cost of other biologics for severe asthma like GlaxoSmithKline's IL-5 inhibitor Nucala (mepolizumab) and Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab ...
pharmaphorum5d
Sanofi’s blockbuster-tipped Dupixent set for European launches
Dupixent (dupilumab) is tipped to be the market leader ... although they are certain to be considerably lower than the US cost. The potential AD market in Europe is very large: the most common ...
Healio5d
Top in allergy/asthma: Dupilumab ineffective for peanut desensitization; asthma blood test
Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...
Investopedia4d
What Are the Types of Costs in Cost Accounting?
Cost accounting is a process that measures all of the expenses associated with running a business, including both fixed and variable costs. The results help management make decisions that optimize ...
Investopedia2d
What Is Cost Accounting? Definition, Concept, and Types
Cost accounting is a process that involves recording, analyzing, and reporting a company's expenses in detail. Unlike financial accounting, cost accounting is an internal process used only by ...
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?
Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.
JD Supra5d
Keeping Watch on Medicare as the IRA is Implemented: Formulary Management Practices
The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.
Regeneron Pharmaceuticals, Inc.: Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.